Published in Proc Natl Acad Sci U S A on December 01, 1977
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1984) 5.49
Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci U S A (1984) 3.35
Clonal recruitment and somatic mutation in the generation of immunological memory to the hapten NP. EMBO J (1986) 2.35
Nucleic acid and protein sequences of phosphocholine-binding light chains. J Exp Med (1981) 1.61
Mutations affecting the structure and function of immunoglobulin M. Mol Cell Biol (1982) 1.58
Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A (1982) 1.46
Somatic mutation in a cultured mouse myeloma cell affects antigen binding. Proc Natl Acad Sci U S A (1982) 1.39
Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol (2009) 1.39
Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11. Nucleic Acids Res (1980) 1.29
Immunoglobulin V region variants in hybridoma cells. I. Isolation of a variant with altered idiotypic and antigen binding specificity. EMBO J (1982) 1.18
Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region. Proc Natl Acad Sci U S A (1987) 1.05
Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations. Am J Pathol (1995) 1.02
Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism. Proc Natl Acad Sci U S A (1989) 1.01
Derivation and diversification of monoclonal antibodies. EMBO J (1985) 0.99
Somatically generated mouse myeloma variants synthesizing IgA half-molecules. J Exp Med (1981) 0.97
A well-differentiated B-cell line is permissive for somatic mutation of a transfected immunoglobulin heavy-chain gene. Proc Natl Acad Sci U S A (1995) 0.93
Mutations that influence the secretory path in animal cells. Biochem J (1983) 0.92
Spontaneous loss and alteration of antigen receptor expression in mature CD4+ T cells. J Exp Med (1990) 0.87
Differential V region mutation of two transfected Ig genes and their interaction in cultured B cell lines. EMBO J (1996) 0.81
Identification of mutant monoclonal antibodies with increased antigen binding. Proc Natl Acad Sci U S A (1988) 0.79
Formation of positive supercoiled DNA by a nuclear factor from myeloma cells. Biochem J (1985) 0.76
Immunoglobulin A stimulates growth of the extrahepatic bile duct in BALB/c mice. Proc Natl Acad Sci U S A (1987) 0.75
Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol (1976) 30.70
An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med (1970) 9.83
Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev (1972) 4.63
Common individual antigenic determinants in five of eight BALB-c IgA myeloma proteins that bind phosphoryl choline. J Exp Med (1970) 4.49
Synthesis, assembly, and secretion of gamma globulin by mouse myeloma cells. I. Adaptation of the Merwin plasma cell tumor-11 to culture, cloning, and characterization of gamma globulin subunits. J Exp Med (1970) 4.26
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site. Proc Natl Acad Sci U S A (1974) 3.92
Growth of primary plasmacytomas in the mineral oil-conditioned peritoneal environment. J Natl Cancer Inst (1972) 3.01
Characterization of the antibody to the C-carbohydrate produced by a transplantable mouse plasmacytoma. Immunochemistry (1969) 2.68
Cloning of mouse myeloma cells and detection of rare variants. J Cell Physiol (1972) 2.63
Clonal nature of the immune response to phosphorylcholine. IV. Idiotypic uniformity of binding site-associated antigenic determinants among mouse antiphosphorylcholine antibodies. J Exp Med (1974) 2.02
Three-dimensional structure of immunoglobulins. Annu Rev Biochem (1975) 1.99
Mutations in immunoglobulin-producing mouse myeloma cells. Science (1973) 1.94
Molecular analysis of spontaneous somatic mutants. Nature (1977) 1.90
Variants of a mouse myeloma cell line that synthesize immunoglobulin heavy chains having an altered serotype. Proc Natl Acad Sci U S A (1975) 1.87
Allogeneic carrier-specific enhancement of hapten-specific secondary B-cell responses. J Exp Med (1976) 1.87
Studies on the structure of mouse gamma-A myeloma proteins. Biochemistry (1968) 1.78
Variants of mouse myeloma cells that produce short immunoglobulin heavy chains. Proc Natl Acad Sci U S A (1974) 1.66
Structural basis for the specificity of phosphorylcholine-binding immunoglobulins. Immunochemistry (1976) 1.63
Mutagenesis of mouse myeloma cells with 'Melphalan'. Nature (1973) 1.27
Size differences among immunoglobulin heavy chains from phosphorylcholine-binding proteins. Proc Natl Acad Sci U S A (1976) 1.27
Specific isolation and characterization of antibody directed to binding site antigenic determinants. J Immunol (1975) 1.06
Mouse myeloma mutants blocked in the assembly, glycosylation and secretion of immunoglobulin. J Mol Biol (1976) 1.03
Synthesis, assembly, and secretion of globulin by mouse myeloma cells. IV. Assembly of IgA. J Immunol (1972) 1.02
Chemical characterization of a mouse immunoglobulin A heavy chain with a 100-residue deletion. Amino acid and carbohydrate compositions and NH2-and COOH-terminal sequences. J Biol Chem (1974) 0.97
Affinity labeling and topology of the antibody combining site. Essays Biochem (1974) 0.96
Three-dimensional structure, function and genetic control of immunoglobulins. Nature (1975) 0.94
Gamma-A half molecules: defective heavy chain mutants in mouse myeloma proteins. J Immunol (1971) 0.93
The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology (1968) 7.42
A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet (1977) 5.65
Synthesis, assembly, and secretion of gamma globulin by mouse myeloma cells. I. Adaptation of the Merwin plasma cell tumor-11 to culture, cloning, and characterization of gamma globulin subunits. J Exp Med (1970) 4.26
The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology (1968) 4.19
Rapidly labeled, polyribosome-associated RNA having the properties of histone messenger. Proc Natl Acad Sci U S A (1967) 4.12
Rate of somatic mutation in immunoglobulin production by mouse myeloma cells. Proc Natl Acad Sci U S A (1971) 3.83
Preparation of mammalian polyribosomes with the detergent Nonidet P-40. Biochim Biophys Acta (1967) 3.81
Use of monoclonal anti-mouse immunoglobulin to detect mouse antibodies. Hybridoma (1981) 3.58
Polyribosomal synthesis and assembly of the H and L chains of gamma globulin. Proc Natl Acad Sci U S A (1966) 3.53
Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci U S A (1984) 3.35
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Somatic cell hybridization of mouse myeloma cells. Cell (1976) 3.17
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods (1992) 2.97
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Cloning of mouse myeloma cells and detection of rare variants. J Cell Physiol (1972) 2.63
The role of somatic hypermutation in the generation of antibody diversity. Science (1989) 2.55
Separate elements control DJ and VDJ rearrangement in a transgenic recombination substrate. EMBO J (1990) 2.52
The Fc receptors of primary and cultured phagocytic cells studied with homogeneous antibodies. J Immunol (1978) 2.38
Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism. Cell (1985) 2.36
Synthesis and assembly of adenovirus 2. I. Polypeptide synthesis, assembly of capsomeres, and morphogenesis of the virion. Virology (1969) 2.27
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med (1991) 2.11
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Extensive allelic variation in Cryptococcus neoformans. J Clin Microbiol (1992) 2.06
The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immunol (1992) 2.02
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Mutations in immunoglobulin-producing mouse myeloma cells. Science (1973) 1.94
Variants of a mouse myeloma cell line that synthesize immunoglobulin heavy chains having an altered serotype. Proc Natl Acad Sci U S A (1975) 1.87
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis (1995) 1.86
Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. J Exp Med (2000) 1.82
Immunoglobulin production: method for quantitatively detecting variant myeloma cells. Science (1970) 1.81
Lymphoblastoid cell lines from patients with chronic lymphocytic leukemia: identification of tumor origin by idiotypic analysis. Proc Natl Acad Sci U S A (1978) 1.78
The polypeptides of adenovirus. 3. Synthesis in infected cells. Virology (1969) 1.77
Heavy chain-producing variants of a mouse myeloma cell line. J Immunol (1975) 1.73
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A (1997) 1.72
Synthesis of ribosomal RNA in synchronized HeLa cells. Nature (1965) 1.69
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature (1966) 1.66
Variants of mouse myeloma cells that produce short immunoglobulin heavy chains. Proc Natl Acad Sci U S A (1974) 1.66
Polyribosome disaggregation during metaphase. Science (1966) 1.61
Effect of adenovirus on host cell DNA synthesis in synchronized cells. Virology (1969) 1.61
Nucleic acid and protein sequences of phosphocholine-binding light chains. J Exp Med (1981) 1.61
Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A (1997) 1.61
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Two kappa immunoglobulin genes are expressed in the myeloma S107. Cell (1981) 1.60
Synthesis of a carboxyl-terminal (constant region) fragment of the immunoglobulin light chain by a mouse myeloma cell line. J Mol Biol (1974) 1.54
Suppression of immunoglobulin synthesis by cellular hybridization. Nat New Biol (1971) 1.50
Rapid thymomas induced by Abelson murine leukemia virus. Proc Natl Acad Sci U S A (1982) 1.49
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother (1994) 1.48
Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A (1982) 1.46
TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. Cell Death Dis (2013) 1.46
Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J Mol Biol (1996) 1.41
Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother (1994) 1.41
Somatic mutation in a cultured mouse myeloma cell affects antigen binding. Proc Natl Acad Sci U S A (1982) 1.39
Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int Immunol (2001) 1.36
IgG2a-producing variants of an IgG2b-producing mouse myeloma cell line. J Exp Med (1978) 1.34
Rat anti-T15 monoclonal antibodies with specificity for VH- and VH-VL epitopes. Mol Immunol (1984) 1.33
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun (2001) 1.32
IgG1 and IgG2b share the Fc receptor on mouse macrophages. J Immunol (1980) 1.31
Fusion of mouse myeloma and spleen cells. Curr Top Microbiol Immunol (1978) 1.30
Regulation of immunoglobulin expression in mouse myeloma cells. Cold Spring Harb Symp Quant Biol (1977) 1.28
Identification of rare immunoglobulin switch variants using the ELISA spot assay. J Immunol Methods (1992) 1.28
Synthesis, assembly, and secretion of gamma globulin by mouse myeloma cells. 3. Assembly of the three subclasses of IgG. J Exp Med (1971) 1.27
Error-prone candidates vie for somatic mutation. J Exp Med (2000) 1.27
Mutagenesis of mouse myeloma cells with 'Melphalan'. Nature (1973) 1.27
Synthesis, assembly and secretion of gamma-globulin by mouse myeloma cells. V. Balanced and unbalanced synthesis of heavy and light chains by IgG-producing tumors and cell lines. J Immunol (1973) 1.26
Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J Exp Med (1998) 1.24
Synthesis and assembly of immunoglobulins by malignant human plasmacytes. I. Myelomas producing gamma-chains and light chains. J Exp Med (1970) 1.23
Point mutations cause the somatic diversification of IgM and IgG2a antiphosphorylcholine antibodies. J Exp Med (1988) 1.23
Characterization of light chain and light chain constant region fragment mRNAs in MPC 11 mouse myeloma cells and variants. Cell (1975) 1.22
The identification of monoclonal class switch variants by sib selection and an ELISA assay. J Immunol Methods (1984) 1.21
Temperature-sensitive mutants of reovirus type 3: studies on the synthesis of viral peptides. Virology (1972) 1.20
The absence of a detectable G1 phase in a cultured strain of Chinese hamster lung cell. J Cell Biol (1967) 1.20
Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med (1996) 1.19
Persistence of messenger RNA through mitosis in HeLa cells. J Cell Biol (1969) 1.19
Synthesis, assembly and secretion of mouse immunoglobulin. Transplant Rev (1973) 1.19
Monoclonal antibodies: a powerful new tool in biology and medicine. Annu Rev Biochem (1981) 1.19
Isolation and sequence of a cDNA corresponding to a src-related gene expressed in murine hemopoietic cells. Proc Natl Acad Sci U S A (1987) 1.17
Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect Immun (1998) 1.14
Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation. Proc Natl Acad Sci U S A (2001) 1.12
Characterization of somatically mutated S107 VH11-encoded anti-DNA autoantibodies derived from autoimmune (NZB x NZW)F1 mice. J Exp Med (1991) 1.10
Synthesis and assembly of immunoglobulins by malignant human plasmacytes and lymphocytes. II. Heterogeneity of assembly in cells producing IgM proteins. J Exp Med (1971) 1.09
Mechanisms of gamma-globulin synthesis. J Immunol (1966) 1.08
Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun (1995) 1.08
Monoclonal antibodies. A new technique for producing serologic reagents. N Engl J Med (1981) 1.08
T-cell receptor and immunoglobulin genes are rearranged together in Abelson virus-transformed pre-B and pre-T cells. Mol Cell Biol (1987) 1.07
Characteristics of cultured lens epithelium. Invest Ophthalmol (1969) 1.07
Somatic diversification of the S107 (T15) VH11 germ-line gene that encodes the heavy-chain variable region of antibodies to double-stranded DNA in (NZB x NZW)F1 mice. Proc Natl Acad Sci U S A (1988) 1.07
Monoclonal antibodies reveal the structural basis of antibody diversity. Science (1983) 1.06
Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region. Proc Natl Acad Sci U S A (1987) 1.05
Mutant monoclonal antibodies with alterations in biological functions. J Exp Med (1982) 1.05
The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer (1994) 1.05
Synthesis and assembly of immunoglobulin polypeptide chains. Prog Allergy (1970) 1.04
Thymocyte subsets transformed by Abelson murine leukemia virus. Mol Cell Biol (1985) 1.03